Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Kathleen K. Christians

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7566-3819; OpenAlex author ID A5059144599. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 9, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2013: 1 paper · 2014: 4 papers · 2015: 5 papers · 2016: 4 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 8 papers · 2021: 3 papers, 1 trial · 2022: none · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 41

  1. AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.0291↗
  2. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  3. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  4. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  5. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  6. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗
  7. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Co-author DOI 10.1002/jso.27265↗
  8. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  9. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  10. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Co-author DOI 10.1007/s10555-021-09993-z↗
  11. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Co-author DOI 10.1016/j.amjsurg.2020.12.001↗
  12. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. First author DOI 10.1245/s10434-020-09149-3↗
  13. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? Co-author DOI 10.1007/s11605-019-04423-6↗
  14. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.anndiagpath.2020.151485↗
  15. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.03.022↗
  16. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  17. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
  18. Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. Last author DOI 10.21037/hbsn.2019.11.26↗
  19. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
  20. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  21. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Last author DOI 10.1016/j.surg.2019.05.010↗
  22. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07906-7↗
  23. Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. Co-author DOI 10.1007/s00261-017-1404-0↗
  24. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/sla.0000000000002957↗
  25. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. First author DOI 10.1007/s11605-016-3319-4↗
  26. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
  27. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Co-author DOI 10.1016/j.prro.2017.06.013↗
  28. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? First author DOI 10.1002/jso.24361↗
  29. Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. Last author DOI 10.1016/j.suc.2016.07.005↗
  30. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.surg.2015.09.018↗
  31. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. First author DOI 10.1200/jop.2016.016162↗
  32. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.06.017↗
  33. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. Co-author DOI 10.1111/hpb.12325↗
  34. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. First author DOI 10.1111/hpb.12448↗
  35. Additional support for neoadjuvant therapy in the management of pancreatic cancer. Co-author DOI 10.1245/s10434-014-4307-0↗
  36. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. First author DOI 10.3978/j.issn.2078-6891.2015.053↗
  37. Optimal management of the splenic vein at the time of venous resection for pancreatic cancer: importance of the inferior mesenteric vein. Last author DOI 10.1007/s11605-013-2428-6↗
  38. Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. First author DOI 10.1007/s11605-014-2635-9↗
  39. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2014.09.010↗
  40. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? First author DOI 10.1111/hpb.12074↗
  41. Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.23166↗

Trials 1

  1. PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples Principal investigator NCT04683315↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas B. Evans · 40 shared papers, 2013–2026 · strength 3.97
  2. Susan Tsai · 38 shared papers, 2013–2026 · strength 3.68
  3. William Adrian Hall · 22 shared papers, 2017–2026 · strength 2.86
  4. Bradley A. Erickson · 29 shared papers, 2014–2024 · strength 2.65
  5. Ben George · 28 shared papers, 2014–2024 · strength 2.59
  6. Mohammed Aldakkak · 21 shared papers, 2015–2026 · strength 2.54
  7. Callisia Nathelee Clarke · 15 shared papers, 2017–2026 · strength 2.00
  8. Mandana Kamgar · 12 shared papers, 2020–2026 · strength 1.96
  9. Kulwinder S. Dua · 9 shared papers, 2018–2025 · strength 1.09
  10. Sam Z. Thalji · 5 shared papers, 2023–2026 · strength 0.91
  11. Beth E. Erickson · 4 shared papers, 2024–2026 · strength 0.81
  12. Parag P. Tolat · 11 shared papers, 2013–2023 · strength 0.81
  13. Ashley N. Krepline · 10 shared papers, 2014–2021 · strength 0.75
  14. Naveen M. Kulkarni · 6 shared papers, 2018–2023 · strength 0.68
  15. Ben George · 3 shared papers, 2024–2026 · strength 0.59
  16. Thomas B. McFall · 3 shared papers, 2024–2026 · strength 0.54
  17. Razelle Kurzrock · 3 shared papers, 2024–2026 · strength 0.54
  18. Chad A. Barnes · 6 shared papers, 2017–2020 · strength 0.53
  19. Nikki K. Lytle · 2 shared papers, 2026 · strength 0.43
  20. Sara Beltrán Ponce · 2 shared papers, 2021–2025 · strength 0.32
  21. Rebecca Y. Kim · 2 shared papers, 2020–2021 · strength 0.31
  22. Catherine E. Hagen · 3 shared papers, 2019–2020 · strength 0.30
  23. Jordan R. Kharofa · 2 shared papers, 2014–2025 · strength 0.24
  24. Fabian Mc. Johnston · 5 shared papers, 2014–2016 · strength 0.24
  25. Anai N. Kothari · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.